|Bid||2.8700 x 2200|
|Ask||2.9000 x 800|
|Day's Range||2.8210 - 2.9300|
|52 Week Range||0.7500 - 5.3000|
|Beta (5Y Monthly)||0.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Evogene Ltd.
Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its financial results for the third quarter ended September 30, 2020.
Canonic, a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN) focused on the development of medical cannabis products, announces today receiving an IMC-GAP approval from the Israel Medical Cannabis Agency for the commercial operation of its propagation farm. This approval will allow Canonic to proceed with the execution of its commercialization plan of medical cannabis products.